{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:27Z","timestamp":1790125707948,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["14\u221235\u201300107"],"award-info":[{"award-number":["14\u221235\u201300107"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01089-3","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T05:03:02Z","timestamp":1615179782000},"page":"987-1000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-3497","authenticated-orcid":false,"given":"Oxana O.","family":"Ryabaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan S.","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Khochenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Akasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly V.","family":"Sholina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A.","family":"Prokofieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur G, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jcp.22647","volume":"226","author":"JA McCubrey","year":"2011","unstructured":"McCubrey JA, Steelman LS, Kempf CR et al (2011) Therapeutic resistance resulting from mutations in Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR signaling pathways. J Cell Physiol 226:2762\u20132781. https:\/\/doi.org\/10.1002\/jcp.22647","journal-title":"J Cell Physiol"},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.07.021","volume":"406","author":"R Calero","year":"2017","unstructured":"Calero R, Morchon E, Martinez-Argudo I, Serrano R (2017) Synergistic anti-tumor effect of 17AAG with the PI3K\/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett 406:1\u201311. https:\/\/doi.org\/10.1016\/j.canlet.2017.07.021","journal-title":"Cancer Lett"},{"key":"1089_CR4","doi-asserted-by":"publisher","unstructured":"Chappell WH, Steelman LS, Long JM, et al (2011) Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135\u2013164. https:\/\/doi.org\/10.18632\/oncotarget.240","DOI":"10.18632\/oncotarget.240"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/iub.1193","volume":"65","author":"A-X Wang","year":"2013","unstructured":"Wang A-X, Qi X-Y (2013) Targeting RAS\/RAF\/MEK\/ERK signaling in metastatic melanoma. IUBMB Life 65:748\u2013758. https:\/\/doi.org\/10.1002\/iub.1193","journal-title":"IUBMB Life"},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72:3228\u20133237. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3747","journal-title":"Cancer Res"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, le NT, Patel K, Lewis KD (2013) Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol Off J Am Soc Clin Oncol 31:482\u2013489. https:\/\/doi.org\/10.1200\/JCO.2012.43.5966","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1089_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CML, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249\u2013256. https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X","journal-title":"Lancet Oncol"},{"key":"1089_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, di Giacomo AM, Rutkowski P, del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Boz\u00f3n V, Long GV, Flaherty K (2017) Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:435\u2013445. https:\/\/doi.org\/10.1016\/S1470-2045(17)30180-8","journal-title":"Lancet Oncol"},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JPJ, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L (2015) Phase II pilot study of Vemurafenib in patients with metastatic BRAF-mutated colorectal Cancer. J Clin Oncol 33:4032\u20134038. https:\/\/doi.org\/10.1200\/JCO.2015.63.2497","journal-title":"J Clin Oncol"},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","volume":"136","author":"U Matulonis","year":"2015","unstructured":"Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S (2015) Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 136:246\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2014.12.019","journal-title":"Gynecol Oncol"},{"key":"1089_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1758834015571111","volume":"7","author":"E Jokinen","year":"2015","unstructured":"Jokinen E, Koivunen JP (2015) MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol 7:170\u2013180. https:\/\/doi.org\/10.1177\/1758834015571111","journal-title":"Ther Adv Med Oncol"},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065\u20133074. https:\/\/doi.org\/10.1172\/JCI34739","journal-title":"J Clin Invest"},{"key":"1089_CR14","doi-asserted-by":"publisher","unstructured":"Sweetlove M, Wrightson E, Kolekar S, Rewcastle GW, Baguley BC, Shepherd PR, Jamieson SMF (2015) Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol 5. https:\/\/doi.org\/10.3389\/fonc.2015.00135","DOI":"10.3389\/fonc.2015.00135"},{"key":"1089_CR15","doi-asserted-by":"publisher","unstructured":"Rewcastle GW, Kolekar S, Buchanan CM, et al (2017) Biological characterization of SN32976, a selective inhibitor of PI3\u03ba and mTOR with preferential activity to PI3\u03ba\u03b1, in comparison to established pan PI3\u03ba inhibitors. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.17730","DOI":"10.18632\/oncotarget.17730"},{"key":"1089_CR16","doi-asserted-by":"publisher","unstructured":"Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC (2015) Potentiation of growth inhibitory responses of the mtor inhibitor everolimus by dual mTORC1\/2 inhibitors in cultured breast cancer cell lines. PLoS One 10. https:\/\/doi.org\/10.1371\/journal.pone.0131400","DOI":"10.1371\/journal.pone.0131400"},{"key":"1089_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2001-1326-1-29","volume":"1","author":"B Seto","year":"2012","unstructured":"Seto B (2012) Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med 1:29. https:\/\/doi.org\/10.1186\/2001-1326-1-29","journal-title":"Clin Transl Med"},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-12-3529","volume":"19","author":"CD Weekes","year":"2013","unstructured":"Weekes CD, Von Hoff DD, Adjei AA et al (2013) Multicenter phase I trial of the mitogen-activated protein kinase 1\/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res An Off J Am Assoc Cancer Res 19:1232\u20131243. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3529","journal-title":"Clin Cancer Res An Off J Am Assoc Cancer Res"},{"key":"1089_CR19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-13-0011","volume":"12","author":"MS Carlino","year":"2013","unstructured":"Carlino MS, Gowrishankar K, Saunders CAB, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, Rizos H (2013) Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and\/or MEK inhibition in melanoma. Mol Cancer Ther 12:1332\u20131342. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0011","journal-title":"Mol Cancer Ther"},{"key":"1089_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.molonc.2014.01.003","volume":"8","author":"MS Carlino","year":"2014","unstructured":"Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H (2014) Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 8:544\u2013554. https:\/\/doi.org\/10.1016\/j.molonc.2014.01.003","journal-title":"Mol Oncol"},{"key":"1089_CR21","unstructured":"Egorov EE, Moldaver MV, Vishniakova KS et al (2007) Enhanced control of proliferation in telomerized cells. Ontogenez"},{"key":"1089_CR22","doi-asserted-by":"publisher","unstructured":"Emelyanova M, Ghukasyan L, Abramov I, et al (2017) Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1\/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis. Oncotarget 8:52304\u201352320. https:\/\/doi.org\/10.18632\/oncotarget.17014","DOI":"10.18632\/oncotarget.17014"},{"key":"1089_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27\u201355","journal-title":"Adv Enzym Regul"},{"key":"1089_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309\u2013324. https:\/\/doi.org\/10.1038\/nprot.2008.226","journal-title":"Nat Protoc"},{"key":"1089_CR25","unstructured":"Mikha\u012dlova IN, Lukashina MI, Baryshnikov AI, et al (2005) [melanoma cell lines as the basis for antitumor vaccine preparation]. Vestn Ross Akad Meditsinskikh Nauk 37\u201340"},{"key":"1089_CR26","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1016\/j.biopha.2018.11.109","volume":"109","author":"O Ryabaya","year":"2019","unstructured":"Ryabaya O, Prokofieva A, Akasov R, Khochenkov D, Emelyanova M, Burov S, Markvicheva E, Inshakov A, Stepanova E (2019) Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells. Biomed Pharmacother 109:2548\u20132560. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.109","journal-title":"Biomed Pharmacother"},{"key":"1089_CR27","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","volume":"71","author":"H Shi","year":"2011","unstructured":"Shi H, Kong X, Ribas A, Lo RS (2011) Combinatorial treatments that overcome PDGFR\u03b2-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71:5067\u20135074. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0140","journal-title":"Cancer Res"},{"key":"1089_CR28","doi-asserted-by":"publisher","unstructured":"Kircher DA, Silvis MR, Cho JH, Holmen SL (2016) Melanoma brain metastasis: mechanisms, models, and medicine. Int J Mol Sci 17. https:\/\/doi.org\/10.3390\/ijms17091468","DOI":"10.3390\/ijms17091468"},{"key":"1089_CR29","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.1200\/jco.2006.24.18_suppl.8043","volume":"24","author":"RD Rao","year":"2006","unstructured":"Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, Suman VJ, Creagan ET, Pitot HC, Markovic SN (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 24:8043\u20138043. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.8043","journal-title":"J Clin Oncol"},{"key":"1089_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147682","volume":"11","author":"MK Kiessling","year":"2016","unstructured":"Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, Oldrige DA, Maris JM, Rogler G (2016) Targeting the mTOR complex by Everolimus in NRAS mutant Neuroblastoma. PLoS One 11:e0147682. https:\/\/doi.org\/10.1371\/journal.pone.0147682","journal-title":"PLoS One"},{"key":"1089_CR31","doi-asserted-by":"publisher","first-page":"9051","DOI":"10.1200\/jco.2014.32.15_suppl.9051","volume":"32","author":"D Juric","year":"2014","unstructured":"Juric D, Soria J-C, Sharma S, Banerji U, Azaro A, Desai J, Ringeisen FP, Kaag A, Radhakrishnan R, Hourcade-Potelleret F, Maacke H, Rodon Ahnert J (2014) A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. J Clin Oncol 32:9051\u20139051. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.9051","journal-title":"J Clin Oncol"},{"key":"1089_CR32","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/bjc.2012.70","volume":"106","author":"EJ Haagensen","year":"2012","unstructured":"Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106:1386\u20131394. https:\/\/doi.org\/10.1038\/bjc.2012.70","journal-title":"Br J Cancer"},{"key":"1089_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12868-018-0482-4","volume":"19","author":"MA Zimmerman","year":"2018","unstructured":"Zimmerman MA, Biggers CD, Li PA (2018) Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride. BMC Neurosci 19:82. https:\/\/doi.org\/10.1186\/s12868-018-0482-4","journal-title":"BMC Neurosci"},{"key":"1089_CR34","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/0008-5472.CAN-19-2366","volume":"80","author":"B Stefanovska","year":"2020","unstructured":"Stefanovska B, Vicier CE, Dayris T, Ogryzko V, Scott V, Bouakka I, Delaloge S, Rocca A, le Saux O, Tr\u00e9dan O, Bachelot T, Andr\u00e9 F, Fromigu\u00e9 O (2020) Rapalog-mediated repression of Tribbles Pseudokinase 3 regulates pre-mRNA splicing. Cancer Res 80:2190\u20132203. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2366","journal-title":"Cancer Res"},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tranon.2016.12.008","volume":"10","author":"YL Wu","year":"2017","unstructured":"Wu YL, Maachani UB, Schweitzer M, Singh R, Wang M, Chang R, Souweidane MM (2017) Dual inhibition of PI3K\/AKT and MEK\/ERK pathways induces synergistic antitumor effects in diffuse intrinsic Pontine Glioma cells. Transl Oncol 10:221\u2013228. https:\/\/doi.org\/10.1016\/j.tranon.2016.12.008","journal-title":"Transl Oncol"},{"key":"1089_CR36","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar PHL (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932\u20131940. https:\/\/doi.org\/10.1038\/sj.onc.1209990","journal-title":"Oncogene"},{"key":"1089_CR37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","volume":"4","author":"Y Shi","year":"2005","unstructured":"Shi Y (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4:1533\u20131540. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0068","journal-title":"Mol Cancer Ther"},{"key":"1089_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113037","volume":"9","author":"TM Pitts","year":"2014","unstructured":"Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S (2014) Dual pharmacological targeting of the MAP kinase and PI3K\/mTOR pathway in preclinical models of colorectal Cancer. PLoS One 9:e113037. https:\/\/doi.org\/10.1371\/journal.pone.0113037","journal-title":"PLoS One"},{"key":"1089_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","volume":"21","author":"PL Bedard","year":"2015","unstructured":"Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, van Cutsem E, P\u00e9rez-Garc\u00eda J, Stathis A, Britten CD, le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C (2015) A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res 21:730\u2013738. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1814","journal-title":"Clin Cancer Res An Off J Am Assoc Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01089-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:17Z","timestamp":1678511237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01089-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01089-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. The protocol to obtain Mel IL cells was initially approved by the N.N. Blokhin National Medical Research Center ethics committee in 1999 with written consent. Since then, the cell line was patented (#RU 2287577 C1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}